A systematic review and meta-analysis of three studies with 1849 participants found that treatment with the Janus kinase inhibitor baricitinib was safe and effective for treating systemic lupus erythematosus (SLE). Baricitinib increased the chances of achieving a Systemic Lupus Erythematosus Responder Index-4 response and reducing Systemic Lupus Erythematosus Disease Activity Index-2000 scores. Additionally, patients treated with baricitinib achieved a significantly lower SLEDAI-2 K score compared to those treated with a placebo. Treatment-emergent adverse events did not differ significantly between the baricitinib and placebo groups. The study concluded that there is now sufficient clinical evidence to support baricitinib’s safety and efficacy in the treatment of SLE.
Source link
Baricitinib Is Safe and Effective for Treating Systemic Lupus Erythematosus
